Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.13 USD | +1.36% | +5.09% | +54.92% |
06-04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
06-03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.92% | 2.49B | |
+75.69% | 12.57B | |
+6.32% | 6.62B | |
+14.03% | 5.45B | |
-16.76% | 4.88B | |
+20.13% | 4.29B | |
-20.25% | 4.06B | |
-22.44% | 2.93B | |
+1.49% | 2.06B | |
+12.16% | 2.01B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- Insider Sell: Novocure